New insights in LUTS/BPH pathophysiology and medical treatment

Poster Session 14

| Location: | Green Area, Room 1 |
| Chairs:   | G.I. Russo, Catania (IT)  
M. Speakman, Taunton (GB)  
T. Tammela, Tampere (FI) |

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

183

5α-Reductase inhibitors and risk of prostate cancer death

By: Bonde Miranda T. 1, Garmo H. 2, Statin P. 3, Robinson D. 1
1Ryhov Hospital, Dept. of Urology, Jonkoping, Sweden, 2Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden, 3Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

Aims and objectives of this presentation

183

184

Dutasteride may change renal morphology?

By: Da Silva M, Sampaio F., De Souza D.
Rio de Janeiro State University, Urogenital Research Unit, Rio de Janeiro, Brazil

Aims and objectives of this presentation

184

185

Neuroactive steroid levels in cerebrospinal fluid of patients treated with dutasteride: A case-control study

By: Favilla V. 1, Cimino S. 1, Alessio P. 1, Li Volti G. 2, Russo G.I. 1, Trovato F. 1, Morgia G. 1
1University of Catania, Dept. of Urology, Catania, Italy, 2University of Catania, Dept. of Biomedical and Biotechnological Sciences, Catania, Italy

Aims and objectives of this presentation

185

187

Long-term effects of tadalafil on storage and voiding function for male patients with detrusor underactivity induced by benign prostatic hyperplasia

By: Matsukawa Y., Takai S., Kanada Y., Ishida S., Majima T., Funahashi Y., Yamamoto T., Gotoh M.
Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
Aims and objectives of this presentation

187

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of overactive bladder associated with benign prostatic hyperplasia (CONTACT Study)

By: Yamanishi T.,1  Kaga K.,2  Sakata K.,3  Yokoyama T.,4  Fuse M.,2  Kaga M.,2  Tokunaga S.5
Dokkyo University School of Medicine, Dept. of Urology, Mibu, Japan,2
Continence Centre, Dokkyo Medical University, Dept. of Urology, Tochigi, Japan,3
Imaichi Hospital, Dept. of Urology, Imaichi, Japan,4
Yokoyama Urological Clinic, Dept. of Urology, Okayama, Japan,5
Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

Aims and objectives of this presentation

188

Mild-to-moderate benign prostatic hyperplasia symptoms: Filling the gap. Efficacy and safety of Afalaza in men with benign prostatic hyperplasia at risk of progression: A multicenter, double-blind, placebo-controlled, randomized clinical trial

By: Vinarov A.Z.,1  Pushkar D.,2  Spivak L.1
Schenov University, Institute for Urology and Reproductive Health, Moscow, Russia,1
Moscow State University of Medicine and Dentistry, Clinic of Urology, Moscow, Russia,2

Aims and objectives of this presentation

189

Correlation of alpha blocker with dementia in patients with benign prostate hyperplasia: A nationwide population-based study using the National Health Insurance Service database

By: Tae B.S.,1  Jeon B.J.,1  Choi H.,1  Park J.Y.,1  Cheon J.,2  Lee J.G.,2  Bae J.H.1
Korea University Ansan Hospital, Dep. of Urology, Ansan, South Korea,1
University Ansan Hospital, Dep. of Urology, Seoul, South Korea,2

Aims and objectives of this presentation

190

Urinary NGF and MMP-1 levels are associated with persistence of detrusor hyperactivity in patients with benign prostatic hyperplasia

By: Barbosa J.A., Sajovic De Conti P., Reis S., Viana N., Nunes M., Nahas W.C.,
Srougi M., Antunes A. A.
University of Sao Paulo Medical School, Dept. of Urology, Sao Paulo, Brazil

Aims and objectives of this presentation

191
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>191</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ghrelin-mediated promotion of prostate growth and prostate smooth muscle contraction: Evidence from functional, in vivo, and genomic approaches</strong></td>
<td></td>
</tr>
<tr>
<td>By: Wang X., Wang Y., Gratzke C., Li B., Yu Q., Strittmatter F., Stief C., Liu C., Hennenberg M.</td>
<td>1 Ludwig-Maximilians University, Dept. of Urology, Munich, Germany, 2 Southern Medical University, Dept. of Urology, Guangzhou, China</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>192</td>
</tr>
<tr>
<td><strong>Inhibition of prostate smooth muscle contraction by NAV2729: Evidence for a role of ADP ribosylation factor 6 (ARF6) for prostate smooth muscle contraction</strong></td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>193</td>
</tr>
<tr>
<td><strong>Withdrawn</strong></td>
<td></td>
</tr>
<tr>
<td><strong>To be confirmed</strong></td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>194</td>
</tr>
<tr>
<td><strong>Autophagy-mediated myofibroblast phenotype and proliferation during the progression of benign prostatic hyperplasia</strong></td>
<td></td>
</tr>
<tr>
<td>By: Song J., Peng X., Jindong S., Yang Y., Shuai H., Jie J.</td>
<td>Peking University First Hospital, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>195</td>
</tr>
<tr>
<td><strong>Estrogen receptor alpha (ERα) antagonist improves benign prostatic hyperplasia (BPH) in high fat induced obesity rat model</strong></td>
<td></td>
</tr>
<tr>
<td>By: Yamanaka N., Mori K., Mizoguchi S., Shin T., Mimata H.</td>
<td>Oita University, Dept. of Urology, Oita, Japan</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>196</td>
</tr>
</tbody>
</table>